Home » Stocks » CLLS

Cellectis S.A. (CLLS)

Stock Price: $15.88 USD 0.88 (5.87%)
Updated May 11, 2021 4:00 PM EDT - Market closed
After-hours: $15.90 +0.02 (0.13%) May 11, 6:22 PM
Market Cap 712.00M
Revenue (ttm) 71.36M
Net Income (ttm) -137.83M
Shares Out 43.04M
EPS (ttm) -2.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $15.88
Previous Close $15.00
Change ($) 0.88
Change (%) 5.87%
Day's Open 15.11
Day's Range 14.84 - 16.30
Day's Volume 345,219
52-Week Range 13.17 - 34.71

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies t...

5 days ago - GlobeNewsWire

With the trading day about halfway over, the broader markets were somewhat mixed. The S&P 500 briefly hit an all-time high and quickly pulled back just after the open.

Other stocks mentioned: ACB, GOOG, GOOGL, NXPI, CROX, ENPH, GOLF ...
1 week ago - 24/7 Wall Street

NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS).

2 weeks ago - GlobeNewsWire

(Article 223-16 of General Regulation of the French financial markets authority)

4 weeks ago - GlobeNewsWire

NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies...

1 month ago - GlobeNewsWire

The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.

Other stocks mentioned: BEAM, CRSP, EDIT, NTLA
1 month ago - InvestorPlace

NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage biotechnological company employing its core proprietary technologies...

1 month ago - GlobeNewsWire

(Article 223-16 of General Regulation of the French financial markets authority)

1 month ago - GlobeNewsWire

Shares of Cellectis (NASDAQ:CLLS) were flatin after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 20.55% year over year to ($0.88), which missed the est...

2 months ago - Benzinga

NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-e...

2 months ago - GlobeNewsWire

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited alloge...

2 months ago - GlobeNewsWire

Cytovia Therapeutics Inc and Cellectis SA (NASDAQ: CLLS) have entered into a strategic research and development collaboration to develop TALEN gene-edited induced pluripotent stem cells (iPSC) Natural K...

2 months ago - Benzinga

CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Natural Killer (NK) and Chimeri...

2 months ago - GlobeNewsWire

(Article 223-16 of General Regulation of the French financial markets authority)

3 months ago - GlobeNewsWire

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared first on In...

Other stocks mentioned: BEAM, CLXT, CRSP, EDIT, NTLA, SGMO
3 months ago - InvestorPlace

(Article 223-16 of General Regulation of the French financial markets authority)

4 months ago - GlobeNewsWire

Cellectis (CLLS) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allog...

4 months ago - GlobeNewsWire

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on developing immunothe...

4 months ago - GlobeNewsWire

(Article 223-16 of General Regulation of the French financial markets authority)

5 months ago - GlobeNewsWire

NEW YORK, Dec. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allog...

5 months ago - GlobeNewsWire

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-to-24 mont...

Other stocks mentioned: ALLO, ATRA, BMY, CRSP, GILD, NVS, PFE
5 months ago - Seeking Alpha

NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cel...

5 months ago - GlobeNewsWire

NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allog...

5 months ago - GlobeNewsWire

(Article 223-16 of General Regulation of the French financial markets authority)

6 months ago - GlobeNewsWire

Cellectis' (CLLS) CEO André Choulika on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-e...

6 months ago - GlobeNewsWire

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allog...

6 months ago - GlobeNewsWire

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited alloge...

6 months ago - GlobeNewsWire

Advancements in gene editing have boosted the biotech space, putting the spotlight on five stocks that can make the most.

Other stocks mentioned: EBS, TMO, VRTX
6 months ago - Zacks Investment Research

NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited ...

8 months ago - GlobeNewsWire

Cellectis S.A. (CLLS) CEO André Choulika on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene...

9 months ago - GlobeNewsWire

NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited al...

9 months ago - GlobeNewsWire

Their groundbreaking research on CAR T-cell therapies could revolutionize how certain cancers are treated in the future.

Other stocks mentioned: ALLO, GILD, NVS, TCRR
9 months ago - The Motley Fool

NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited al...

9 months ago - GlobeNewsWire

Dr. Yves Ribeill, Member of Calyxt’s Board of Directors since 2018, Appointed Chairman of the Board; Laurent Arthaud named Director, designated by Cellectis Dr. Yves Ribeill, Member of Calyxt’s Board of...

10 months ago - GlobeNewsWire

NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T...

10 months ago - GlobeNewsWire

Is (CLLS) Outperforming Other Medical Stocks This Year?

10 months ago - Zacks Investment Research

NEW YORK, June 29, 2020 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 29, 2020 at its head office in Paris, France.

10 months ago - GlobeNewsWire

Cellectis has shown promise in its oncology treatment and a new paper shows that it's able to overcome early risk detection.

10 months ago - Seeking Alpha

NEW YORK, June 25, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-...

10 months ago - GlobeNewsWire

Cellectis S.A. (CLLS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Cellectis.

11 months ago - Zacks Investment Research

NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited all...

11 months ago - GlobeNewsWire

Cellectis (CLLS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

(Article 223-16 of General Regulation of the French financial markets authority)

11 months ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for May 12th

Other stocks mentioned: CHGG, HEAR, ISEE
11 months ago - Zacks Investment Research

Cellectis' (CLLS) CEO André Choulika on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Industry veteran joins Cellectis leadership team as UCART product pipeline advances in clinical trials Industry veteran joins Cellectis leadership team as UCART product pipeline advances in clinical trials

1 year ago - GlobeNewsWire

About CLLS

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 7, 2007
CEO
Andre Choulika
Employees
272
Stock Exchange
NASDAQ
Ticker Symbol
CLLS
Full Company Profile

Financial Performance

In 2020, Cellectis's revenue was 82.46 million, an increase of 258.66% compared to the previous year's 22.99 million. Losses were -81.07 million, -20.59% less than in 2019.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Cellectis stock is "Buy." The 12-month stock price forecast is 34.89, which is an increase of 119.71% from the latest price.

Price Target
$34.89
(119.71% upside)
Analyst Consensus: Buy